Receptor Tyrosine-Kinases Inhibition: New Insights on Therapeutic Implications of EGFR and IGF1R in Human Bronchopulmonary NET Abstract #1039

Introduction: The main treatment for bronchopulmonary NET(BP-NET) is surgery, which is not feasible for infiltrating and metastatic disease, where medical therapy is tried. Identifying new therapeutic targets is important to provide adequate medical treatment for patients with BP-NET. Sunitinib, a multi-targeted receptor tyrosine kinase inhibitor (TKI), is mainly described to inhibit VEGF
Aim(s): To verify if IGF1R and EGFR could be involved in Sunitinib mechanism of action in BP-NET
Materials and methods: Human BP-NET cell lines and human BP primary cultures were treated with sunitinib and/or EGF, IGF1, or VEGF. Cell viability and caspase 3/7 activation were measured after 48 h of treatment. Receptor expression was detected by Western blot in cell lines and primary cultures. IGF1R and EGFR phosphorylation was analysed by alphascreen sure fire assay
Conference: 12th Annual ENETS Conference (2015)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Dr Teresa Gagliano
Keywords: RTK, BP-NET, IGF1R, EGFR

To read results and conclusion, please login ...

Further abstracts you may be interested in

#933 The Cytotoxic Effect of Sunitinib on Human Bronchial Carcinoid Cell Lines and Primary Cultures is Counteracted by EGF and IGF-1, but not by VEGF
Introduction: Bronchial carcinoids (BC) are rare tumors originating from endocrine cells dispersed in the respiratory epithelium. The main BC treatment is surgery, but which is not feasible for large, infiltrating and metastatic disease. In these settings, medical therapy is often tried. Therefore it is important to identify new therapeutic targets and new molecules capable of providing adequate medical treatment for patients with BC. Sunitinib is an oral, small-molecule, multi-targeted receptor tyrosine kinase inhibitor.
Conference: 11th Annual ENETS Conference (2014)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Dr Teresa Gagliano
Keywords: BC, RTK, Sunitinib
#1462 Cross-Talk Between EGFR and IGF1R Influences the Response to RTK Inhibitors in Bronchopulmonary (BP)-NET Cell Lines
Introduction: BP-NETs represent ~30% of all neuroendocrine tumors. BP-NET treatment is challenging due to onset of resistance to chemo and targeted therapies. EGFR and IGF1R had been associated with tumor onset and progression in several neoplasia.
Conference: 13th Annual ENETS conference (2016)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Dr Teresa Gagliano
Keywords: BP-NET RTK
#1086 mTOR Down-Stream Signaling Pattern May Predict pNET Response to Everolimus
Introduction: NETs are rare neoplasms arising from neuroendocrine cells spread in the respiratory and gastro-entero-pancreatic epithelium. The mammalian target of rapamycin (mTOR) pathway plays a central role in the regulation of cell growth, metabolism, and apoptosis representing a novel molecular target. This pathway is constitutively activated in pancreatic NETs (pNETs) providing the basis for the development of specific mTOR inhibitors as new therapeutic tools.
Conference: 12th Annual ENETS Conference (2015)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: PhD student Simona Falletta
Keywords: pNET, Everolimus, mTOR
#680 Role of EGF Pathway in Regulating Bronchial Carcinoid Cell Proliferation
Introduction: Bronchial carcinoids (BC) are rare neuroendocrine tumors. Surgery is not feasible for infiltrating and metastatic disease. Medical therapy is often tried but is represented by chemotherapy and radiation, while somatostatin analogues are employed for symptomatic control. It is necessary to identify new molecules capable of providing medical treatment in cases for which surgical removal is not feasible. EGF, TGFα are growth factors which were demonstrated to be important in neuroendocrine tumors. EGF and TGFα bind to the EGF receptor and lead to the transcription of genes that regulate cell proliferation.
Conference: 10th Annual ENETS Conference (2013)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Dr Teresa Gagliano
Keywords: EGF, EGFR, BC
#1089 Role of TGF beta-1 in Regulating Pancreatic Neuroendocrine Tumor Cell Viability
Introduction: Neuroendocrine tumors (NETs) are heterogeneous neoplasms arising from neuroendocrine cells spread in the respiratory and gastro-entero-pancreatic epithelium. The role of transforming growth factor beta-1 (TGF b-1) in NET biology is largely unknown. TGF b-1 signaling pathway is tumor suppressive in most non-transformed epithelial cell lines. In contrast, many human carcinomas are refractory to the growth–inhibitory effects of TGF b-1.
Conference: 12th Annual ENETS Conference (2015)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: PhD student Simona Falletta
Keywords: pNET, TGF-b1, Everolimus